Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start : Episode 10

Opinion

Video

June 14, 2024

Addressing Suboptimal Treatment Response in HIV

Author(s):

Paul E. Sax, MD,Shauna Applin, ARNP

A panel of experts on HIV discuss decision-making practices for patients who have suboptimal response to their current treatment regimen.

EP: 1.The Role of the Primary Care Provider/Advanced Practice Provider in HIV Management

EP: 2.Evolving Treatment Practices and Guidelines for HIV

EP: 3.Key Clinical Considerations in HIV Treatment Decisions

EP: 4.HIV Treatment: Discussing Adverse Events with Patients

EP: 5.Importance of Starting HIV Treatment Early

EP: 6.Treatment Resistance in HIV

EP: 7.HIV Drug Resistance Testing Practices and Patient Education

EP: 8.Managing Suboptimal Adherence to HIV Medications

EP: 9.HIV Treatment Clinical Experiences

EP: 10.Addressing Suboptimal Treatment Response in HIV

EP: 11.Current HIV Treatment Regimens

EP: 12.Rapid Treatment Initiation in HIV

EP: 13.Switching Therapies for Patients with HIV and History of Resistance

EP: 14.Resources Available for Patients with HIV Drug Resistance

EP: 15.Factors that Inform Treatment Selection in HIV

EP: 16.Switching Therapies in HIV

EP: 17.Restarting Therapy in Patients with HIV

EP: 18.Treatment Guidelines and Regimens for Managing Patients with HIV

EP: 19.Differences in Binding Affinity Between Integrase Inhibitors in HIV

EP: 20.Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens

EP: 21.Recent Studies on HIV Treatments and Patient-Reported Outcomes

EP: 22.HIV: Treating Patients with Viral Mutations

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following question:

How do you manage a patient with HIV who has a suboptimal response to their current treatment regimen?

Related Videos

4 experts are featured in this series.

4 experts are featured in this series.

4 experts are featured in this series.

4 experts are featured in this series.

Related Content

Doctor talking to patient | Credit: Fotolia

September 28th 2023

Study Highlights Safety, Efficacy of FMT for Patients with HIV

Abigail Brooks, MA

The Power of the Primary Care Visit to Combat COVID-19 and HIV

April 19th 2023

The Power of the Primary Care Visit to Combat COVID-19 and HIV

Annette Gadegbeku, MD Leon McCrea, MD, MPH

The FDA's Blood Donor Amendment for MSM is a Correction, not a Victory

February 6th 2023

The FDA's Blood Donor Amendment for MSM is a Correction, not a Victory

Strategies Are Developing to Boost HIV PrEP Initiation

December 15th 2021

Strategies Are Developing to Boost HIV PrEP Initiation

John Parkinson Nina Cosdon

T-Cell Levels Determine Mortality Risk for HIV, HBV Positive Patients

September 13th 2021

T-Cell Levels Determine Mortality Risk for HIV, HBV Positive Patients

HIV Care During COVID-19

March 11th 2021

HIV Care During COVID-19

Related Content

Doctor talking to patient | Credit: Fotolia

September 28th 2023

Study Highlights Safety, Efficacy of FMT for Patients with HIV

Abigail Brooks, MA

The Power of the Primary Care Visit to Combat COVID-19 and HIV

April 19th 2023

The Power of the Primary Care Visit to Combat COVID-19 and HIV

Annette Gadegbeku, MD Leon McCrea, MD, MPH

The FDA's Blood Donor Amendment for MSM is a Correction, not a Victory

February 6th 2023

The FDA's Blood Donor Amendment for MSM is a Correction, not a Victory

Strategies Are Developing to Boost HIV PrEP Initiation

December 15th 2021

Strategies Are Developing to Boost HIV PrEP Initiation

John Parkinson Nina Cosdon

T-Cell Levels Determine Mortality Risk for HIV, HBV Positive Patients

September 13th 2021

T-Cell Levels Determine Mortality Risk for HIV, HBV Positive Patients

HIV Care During COVID-19

March 11th 2021

HIV Care During COVID-19

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.